Revolutionizing Gene Editing: A $2 Million Grant to Cure Diseases
Imagine being able to cure genetic diseases without the risk of unwanted mutations. Sounds like science fiction, right?
A University of Hawaiʻi at Mānoa researcher has taken a significant step closer to making this a reality. Jesse Owens, associate professor at the John A. Burns School of Medicine's Department of Cell and Molecular Biology, has been awarded a $2 million grant from the National Institutes of Health (NIH) to advance his gene-editing technology.
The Dream Grant
"This grant is a dream come true," Owens exclaimed. "It funds our passion project – developing safer, more precise tools for gene therapy that can be used across various diseases." The four-year grant will support Owens' effort to create a new generation of transposases, specialized enzymes that insert genes into precise genome locations.
A Safer Approach to Gene Editing
Unlike CRISPR, which cuts DNA and can lead to unwanted mutations, Owens' method replaces genes without cutting or exposing the DNA, allowing for safer and more precise gene delivery. This precision is the result of years of meticulous research, including testing over 200 mutated enzymes to find one that makes minimal mistakes and changes only the intended genes.
The Challenge of Precision
The lab's next goal is to improve the system's "on-target" efficiency – the rate at which genes land exactly where intended. "We've minimized the off-target effects; now we're working on boosting the on-target performance so that the system is both incredibly safe and incredibly effective," Owens said.
A Leap Forward in Efficiency
Owens' lab has made remarkable progress, achieving nearly 100% efficiency in gene delivery, a significant leap from the early versions that achieved less than 1% efficiency. "What we didn’t realize early on was just how fine-tuned this system needed to be," Owens reflected. "If you move the target by just two base pairs, the efficiency can drop dramatically."
Fighting Many Diseases
Owens describes his lab as "disease agnostic," building tools that can be applied broadly, from hemophilia to cystic fibrosis to cancer. "It's a special type of grant," he explained. "It's not tied to one disease area, which is perfect for us. We can focus on making the best tool possible, and then share it with researchers who specialize in different diseases."
Accelerating Cancer Treatment
Ultimately, Owens hopes the technology will accelerate CAR T immunotherapy, which reprograms immune cells to destroy cancer. "The really exciting thing is that this could one day help treat actual patients," Owens said. "Imagine something that started in your PhD eventually becoming part of a therapy that fights cancer. That’s what drives us."
Inspiring the Next Generation
The grant also supports two JABSOM graduate students, providing hands-on experience at the forefront of gene therapy research. "Dr. Owens and his team are not only advancing the science of gene editing, they’re inspiring the next generation of scientists who will continue our legacy of innovation and discovery," said JABSOM Dean Sam Shomaker.
The Future of Gene Editing
As Owens and his team continue their groundbreaking research, the possibilities for gene editing technology are vast. But here's where it gets interesting – could this technology lead to a new era of personalized medicine? Or will it raise concerns about the ethics of gene editing? We want to hear from you – share your thoughts in the comments!
